P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro

Genes and Development

Volumn 11, Issue 20, 1997, Pages 2633-2644

  Mancebo, Helena S Y ^a   Lee, Gary ^a   Flygare, John ^a   Tomassini, Joanne ^c   Luu, Percy ^a   Zhu, Yuerong ^b   Peng, Junmin ^b   Blau, Carol ^c   Hazuda, Daria ^c   Price, David ^b   Flores, Osvaldo ^a  

^a AMGEN INC   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

HIV Tat protein; Kinase inhibitors; P TEFb kinase; Transcriptional activation

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; ANTIVIRUS AGENT; ELONGATION FACTOR; HA 100; N (2 GUANIDINOETHYL) 5 ISOQUINOLINESULFONAMIDE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; T 163693; T 172298; T 172299; T 174557; T 276339; T 525636; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CONTROLLED STUDY; DROSOPHILA; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; LONG TERMINAL REPEAT; NONHUMAN; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; TRANSACTIVATION; TRANSCRIPTION REGULATION; VIRUS TRANSCRIPTION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 14444281157     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.11.20.2633     Document Type: Article

References (45)

1. Akoulitchev, S., T.P. Makela, R.A. Weinberg, and D. Reinberg. 1995. Requirement for IIH kinase activity in transcription by RNA polymerase II. Nature 377: 557-560.
2. Ausubel, F., R. Brent, R.E. Kingston, D. Moore, J.G. Seidman, J.A. Smith, and K. Struhl. 1995. RNase protection assay. In Current protocols in molecular biology. Vol. 1, pp. 4.7.1-4.7.8. Greene-Wiley, New York, NY.
3. Blau, J., H. Xiao, S. McCracken, P. O'Hare, J. Greenblatt, and D. Bentley. 1996. Three functional classes of transcriptional activation domains. Mol. Cell. Biol. 16: 2044-2055.
4. Byrnes, V. and D. Hazuda. 1996. A system to analyze and identify inhibitors of HIV-1 gene regulation using a defective integrated provirus. Methods Enzymol. 275:348-361.
5. Chang, C., C.F. Kostrub, and Z.F. Burton. 1993. RAP30/74 (transcription factor IIF) is required for promoter escape by RNA polymerase II. J. Biol. Chem. 268: 20482-20489.
6. Chodosh, L.A., A. Fire, M. Samuels, and P.A. Sharp. 1989. 5,6-Dichloro-1 -beta-D-ribofuranosylbenzimidazole inhibits transcription elongation by RNA polymerase II in vitro. J. Biol. Chem. 264: 2250-2257.
7. Dahmus, M.E. 1996. Reversible phosphorylation of the C-terminal domain of RNA polymerase II. J. Biol. Chem. 271: 19009-19012.
8. Feinberg, M.B., D. Baltimore, and A.D. Frankel. 1991. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc. Natl. Acad. Sci. 88: 4045-4059.
9. Flores, O., H. Lu, and D. Reinberg. 1992. Factors involved in specific transcription by mammalian RNA polymerase II. Identification and characterization of factor IIH. J. Biol. Chem. 267: 2786-2793.
10. Fraser, N.W., P.B. Sehgal, and D.E. Darnell, Jr. 1979. Multiple discrete sites for premature RNA chain termination late in adenovirus-2 infection: Enhancement by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole. Proc. Natl. Acad. Sci. 76:2571-2575.
11. Garcia-Martinez, L.F., G. Mavankal, J.M. Neveu, W.S. Lane, D. Ivanov, and R.B. Gaynor. 1997. Purification of a Tat-associated kinase reveals a TFIIH complex that modulates HIV-1 transcription. EMBO J. 16: 2836-2850.
12. Goodrich, J.A. and R. Tjian. 1994. Transcription factors II and IIH and ATP hydrolysis direct promoter clearance by RNA polymerase II. Cell 77: 145-156.
13. Ha, I, W.S. Lane, and D. Reinberg. 1991. Cloning of a human gene encoding the general transcription initiation factor IIB. Nature 352: 689-695.
14. Herrmann, C.H. and A.P. Rice. 1993. Specific interaction of the human immunodeficiency virus Tat proteins with a cellular protein kinase. Virology 197: 601-608.
15. _. 1995. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: Candidate for a Tat cofactor. J. Virol. 69: 1612-1620.
16. Hsu, M.C., A.D. Schutt, M. Holly, L,W Slice, M.I. Sherman, D.D. Richman, M.J. Potash, and D.J. Volsky. 1992. Discovery and characterization of an HIV-1 Tat antagonist.Biochem. Soc. Trans. 20:525-531.
17. Jones, K.A. and B.M. Peterlin. 1994. Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63:717-743.
18. Klucher, K.M., M. Sommer, J.T. Kadonaga, and D.H. Spector. 1993. In vivo and in vitro analysis of transcriptional activation mediated by the human cytomegalovirus major immediate-early proteins. Mol. Cell. Biol. 13: 1238-1250.
19. Krumm, A., L.B. Hickey, and M. Groudine. 1995. Promoterproximal pausing of RNA polymerase II defines a general rate-limiting step after transcription initiation. Genes & Dev. 9: 559-572.
20. Laspia, M.F., A.P. Rice, and M.B. Mathews. 1989. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 59: 283-292.
21. _. 1990. Synergy between HIV-1 Tat andadenovirus E1A is principally due to stabilization of transcriptional elongation. Genes &. Dev. 4: 2397-2408.
22. Laub, O., E.B. Jakobovits, and Y. Aloni. 1980. 5,6-dichloro-1-beta-ribofuranosylbenzimidazole enhances premature termination of late transcription of Simian virus 40 DNA. Proc. Natl. Acad. Sci. 77:3297-3301.
23. Lee, G., J. Wu, P. Luu, P. Ghazal, and O. Flores. 1996. Inhibition of the association of RNA polymerase II with the preinitiation complex by a viral transcriptional repressor. Proc. Natl. Acad. Sci. 93: 2570-2575.
24. Lu, H., O. Flores, R. Weinmann, and D. Reinberg. 1991. The nonphosphorylated form of RNA polymerase II preferentially associates with the preinitiation complex. Proc. Natl. Acad. Sci. 88: 10004-10008.
25. Marciniak, R.A. and P.A. Sharp. 1991. HIV-1 Tat protein promotes formation of more-processive elongation complexes. EMBO J. 10:4189-4196.
26. Marciniak, R.A., B.J. Calnan, A.D. Frankel, and P.A. Sharp. 1990. HIV-1 Tat protein trans-activates transcription in vitro. Cell 63:791-802.
27. Marshall, N.F., J. Peng, Z. Xie, and D.H. Price. 1996. Control of RNA polymerase II elongation potential by a novel carboxylterminal domain kinase. J. Biol. Chem. 271:27176-27183.
28. Michne, W.F., J.D. Schroeder, T.R. Bailey, H.C. Neumann, D. Cooke, D.C. Young, J.V. Hughes, S.D. Kingsley, K.A. Ryan, H.S. Putz et al. 1995. Keto/enol epoxy steroids as HIV-1 Tat inhibitors: Structure-activity relationships and pharmaco-phore localization. J. Med. Chem. 38:3197-3206.
29. Newstein, M., E.J. Stanbridge, G. Casey, and P.R. Shank. 1990. Human chromosome 12 encodes a species-specific factor which increases human immunodeficiency virus type 1 Tatmediated transactivation in rodent cells, J. Virol. 64: 4565-4567.
30. Parada, C.A. and R.G. Roeder. 1996. Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature 384: 375-378.
31. Peterson, M.G., J. Inostroza, M.E. Maxon, O. Flores, A. Admon, D. Reinberg, and R. Tjian. 1991. Structure and functional properties of human general transcription factor IIE. Nature 354: 369-373.
32. Reinberg, D., M. Horikoshi, and R.G. Roeder. 1987. Factors involved in specific transcription in mammalian RNA polymerase II. Functional analysis of initiation factors IIA and IID and identification of a new factor operating at sequences downstream of the initiation site. J. Biol. Chem. 262: 3322-3330.
33. Sheline, C.T., L.H. Milocco, and K.A. Jones. 1991. Two distinct nuclear transcription factors recognize loop and bulge residues of the HIV-1 TAR RNA hairpin. Genes & Dev. 5: 2508-2520.
34. Tamm, I. and T. Kikuchi. 1979. Early termination of heterogeneous nuclear RNA transcripts in mammalian cells: Accentuation by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole. Proc. Natl. Acad. Sci. 76: 5750-5754.
35. Tweeten, K.A. and G.R. Molloy. 1981. Induction of premature termination of transcription of the mouse beta-globin gene by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB). Nucleic Acids Res. 9: 3307-3319.
36. Winslow, B.J. and D. Trono. 1993. The blocks to human immunodeficiency virus type 1 Tat and Rev functions in mouse cell lines are independent. J. Virol. 67: 2349-2354.
37. Yang, X., C.H. Herrmann, and A.P. Rice. 1996. The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function. J. Virol. 70: 4576-4584.
38. Yankulov, K., J Blau, T. Purton, S. Roberts, and D.L. Bentley. 1994. Transcriptional elongation by RNA polymerase II is stimulated by transactivators. Cell 77: 749-759.
39. Yankulov, K.Y., M. Pandes, S. McCracken, D. Bouchard, and D.L. Bentley. 1996. TFIIH functions in regulating transcriptional elongation by RNA polymerase II in Xenopus oocytes. Mol. Cell. Biol. 16:3291-3299.
40. Zandomeni, R. and R. Weinmann. 1984. Inhibitory effect of 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole on a protein kinase. J. Biol. Chem. 259: 14804-14811.
41. Zandomeni, R., M.C. Zandomeni, D. Shugar, and R. Weinmann. 1986. Casein kinase type II is involved in the inhibition by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole of specific RNA polymerase II transcription, J. Biol. Chem. 261: 3414-3419.
42. Zhou, Q. and P.A. Sharp. 1995. Novel mechanism and factor for regulation by HIV-1 Tat. EMBO J. 14: 321-328.
43. _. 1996. Tat-SF1: Cofactor for stimulation of transcriptional elongation by HIV-1 Tat. Science 274: 605-610.
44. Zhu, Y., T. Pe'ery, J. Peng, Y. Ramanathan, N. Marshall, T. Marshall, B. Amendt, M.B. Mathews, and D.H. Price. 1997. Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro. Genes & Dev. (this issue).
45. Zou, R., K.R. Ayres, J.C. Drach, and L.B Townsend. 1996. Synthesis and antiviral evaluation of certain disubstituted benzimidazole ribonucleosides. J. Med. Chem. 39: 3477-3482.